Table II.
Sex | |
Male | 6 (55%) |
| |
Race | |
White | 10 (91%) |
Asian | 1 (9%) |
| |
Age at study enrollment (years)* | 11.1 (9.3–17.3) |
| |
Parent education# | |
High School or less | 3 (27%) |
High school + some college | 8 (73%) |
| |
Annual household Income# | |
<20,000 | 1(8%) |
20–34,999 | 3 (25%) |
35,000–49,999 | 2 (17%) |
75,0000+ | 5(45%) |
| |
Parent marital status (married)# | 7 (63%) |
| |
Diagnosis | |
Medulloblastoma | 7 |
Craniopharyngioma | 1 |
Pilocytic astrocytoma | 1 |
Ependymoma | 1 |
Pineoblastoma | 1 |
| |
Age at cranial RT* | 5.55 (3.4–13.2) |
| |
Cranial RT Dose (Gy)* | 55.8 (50.4–60.3) |
| |
Median time since radiation (years) | 4.7 (1.9–11.9) |
| |
Chemotherapy treatment | |
Yes | 8 (73%) |
| |
Lansky/Karnofsky performance status | 90 (70–100) |
| |
Endocrinopathy## | |
| |
GH deficiency | 7 (64%) |
| |
Cortisol deficiency | 3 (27%) |
| |
Hypothyroidism | 7 (64%) |
| |
VP shunt | 2 (18%) |
| |
Cranial nerve deficit | 7 (64%) |
| |
Gross motor deficit | 6 (55%) |
Median and range;
based on CHRIS demographics;
RT= radiation therapy;
Mean(sd) Intelligence quotient (IQ) measured by Weschler Abbreviated Scale of Intelligence(WASI)(44);
Patients on hormone replacement therapy at time of study